Iteos Therapeutics Inc (ITOS) — Cash Flow Quality Index

Latest as of December 2022: -1.33x

Iteos Therapeutics Inc (ITOS) has a Cash Flow Quality Index of -1.33x as of December 2022. Operating cash flow of $-27.17 Million is below net income of $20.45 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore ITOS strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.

Cash Flow Quality Index

-1.33x
Operating CF / Net Income

Operating Cash Flow

$-27.17 Million
USD

Net Income

$20.45 Million
USD

Data as of

Dec 2022
Most recent filing

Iteos Therapeutics Inc Cash Flow Quality Index (2021–2022)

Historical Cash Flow Quality Index for Iteos Therapeutics Inc across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check how tangible is Iteos Therapeutics Inc's equity to evaluate the tangible quality of the company's equity base.

Annual Cash Flow Quality Index for Iteos Therapeutics Inc (2021–2022)

Year-by-year earnings quality comparison for Iteos Therapeutics Inc. For live market cap and the full company financial profile, see Iteos Therapeutics Inc (ITOS) total market value.

Year Quality Index Operating CF (USD) Net Income YoY Change
2022 -1.15x $-111.19 Million $96.65 Million ▼ -148.1%
2021 2.39x $513.14 Million $214.52 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.